Novo Nordisk has reported that its oral semaglutide medicine showed non-inferiority compared to...
Arecor’s ultra-rapid acting insulin shows promise in Phase I trial
UK-based biopharmaceutical firm Arecor has announced that its ultra-rapid acting insulin candidate, AT247, demonstrated encouraging pharmacokinetic and pharmacodynamic profiles in a Phase I clinical trial.
Rexgenero opens enrolment for SALAMANDER trials in UK
Rexgenero has opened the first site in the UK to enrol diabetic patients with chronic limb-threatening ischemia (CLI) for the Phase III SALAMANDER studies of REX-001.
Ardelyx reports positive data from tenapanor’s Phase III CKD trial
Ardelyx has reported positive top-line data from Phase III PHREEDOM clinical trial of tenapanor to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
Ionis and Akcea launch Phase III trial to treat polyneuropathy
Ionis Pharmaceuticals and its affiliate Akcea Therapeutics have launched a Phase III clinical trial of AKCEA-TTR-L to treat polyneuropathy in patients with hereditary TTR (hATTR) amyloidosis.
CymaBay suspends liver disease trials of seladelpar
CymaBay Therapeutics has announced the termination of Phase IIb and Phase II clinical trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), respectively.
Daiichi Sankyo’s Phase III trial of esaxerenone meets primary goal
Daiichi Sankyo has reported positive data from the Phase III clinical trial of esaxerenone to treat patients with incipient diabetic nephropathy, which is type 2 diabetes with microalbuminuria, in Japan.
Sanofi reports positive data for Toujeo in Phase III diabetes study
Sanofi has reported positive results from the Phase III clinical trial of Toujeo for the treatment of children and adolescents with type 1 diabetes.
Trial finds new cell therapy safe for live cirrhosis treatment
Researchers from the MRC Centre for Regenerative Medicine at the UK's University of Edinburgh have reported positive results from a clinical trial that assessed a new cell therapy for liver cirrhosis.
CytoDyn to assess leronlimab in Phase II NASH trial
CytoDyn has secured US Food and Drug Administration (FDA) clearance to begin patient enrolment in a Phase II clinical trial of leronlimab (PRO 140) to treat non-alcoholic steatohepatitis (NASH).
Medicines Company’s inclisiran meets all endpoints in ORION-10 trial
The Medicines Company has reported positive results from the Phase III ORION-10 clinical trial, where cholesterol-lowering drug inclisiran met all primary and secondary endpoints in atherosclerotic cardiovascular disease (ASCVD) patients.